HOWL Werewolf Therapeutics, Inc.
Distress ·
Werewolf expects a one-time charge of approximately $4.1 million in the first quarter of 2026. The filing also discloses the company's efforts to raise capital and a review of strategic partnerships for WTX-124 and WTX-330.
The death of director Dr. Alon Lazarus on September 30, 2025 left Werewolf's audit committee with two members, one short of Nasdaq's three-member minimum. The company plans to appoint an independent director at its earliest opportunity.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $0 | $1.9 million |
| Research and development | $44.8 million | $56.4 million |
| Net income (loss) | -$60.8 million | -$70.5 million |
| Cash from operations | -$60.3 million | -$56.2 million |
| Cash and equivalents | $57.0 million | $111.0 million |
Werewolf Therapeutics, Inc. trades under the ticker HOWL on NASDAQ.
Werewolf Therapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Werewolf Therapeutics, Inc. is 1785530. Its filings are on SEC EDGAR.
48,599,066 shares as of 2026-07-27, per the cover page of its 10-Q filed 2026-07-31.
Our directory records Werewolf Therapeutics, Inc. under United States.
Our directory classifies Werewolf Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Werewolf Therapeutics, Inc. is US95075A1079.
aibio.space lists Werewolf Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
$0 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Werewolf Therapeutics, Inc. reported a net loss of $60.8 million for the fiscal year ended Dec 31, 2025, and used $60.3 million of cash in operations, per its annual report to the SEC.
$44.8 million in the fiscal year ended Dec 31, 2025, per its annual report.
$22.0 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on Werewolf Therapeutics, dated Feb 13, 2026: "Werewolf Therapeutics cuts 64% of workforce; CFO and CMO resign". Werewolf expects a one-time charge of approximately $4.1 million in the first quarter of 2026. The filing also discloses the company's efforts to raise capital and a review of strategic partnerships for WTX-124 and WTX-330. Source.
Our latest distress story, dated Feb 13, 2026: "Werewolf Therapeutics cuts 64% of workforce; CFO and CMO resign". Werewolf expects a one-time charge of approximately $4.1 million in the first quarter of 2026. The filing also discloses the company's efforts to raise capital and a review of strategic partnerships for WTX-124 and WTX-330. Source.
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 8.01,9.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,5.02,7.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio